FCM
CLDX icon

Frontier Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Frontier Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,609
Closed -$498K – 323
2017
Q3 		$498K Sell
11,609
-82,873
-88% -$3.11M ﹤0.01% 283
2017
Q2 		$3.5M Sell
94,482
-8,081
-8% -$357K 0.03% 279
2017
Q1 		$5.55M Sell
102,563
-1,817
-2% -$94.6K 0.04% 268
2016
Q4 		$5.54M Sell
104,380
-2,758
-3% -$157K 0.04% 259
2016
Q3 		$6.49M Sell
107,138
-16,847
-14% -$1.05M 0.05% 261
2016
Q2 		$8.16M Sell
123,985
-18,596
-13% -$1.18M 0.07% 249
2016
Q1 		$8.08M Sell
142,581
-13,132
-8% -$1.48M 0.06% 252
2015
Q4 		$36.6M Sell
155,713
-77,534
-33% -$16.9M 0.3% 116
2015
Q3 		$36.9M Buy
233,247
+66,858
+40% +$18.9M 0.31% 117
2015
Q2 		$62.9M Buy
166,389
+122,620
+280% +$48.7M 0.45% 69
2015
Q1 		$18.3M Sell
43,769
-34,939
-44% -$12.5M 0.13% 225
2014
Q4 		$21.5M Buy
78,708
+14,854
+23% +$3.69M 0.16% 194
2014
Q3 		$12.4M Buy
63,854
+2,328
+4% +$507K 0.1% 235
2014
Q2 		$15.1M Buy
+61,526
New +$13.9M 0.11% 225

Other funds holding CLDX

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Frontier Capital Management's CLDX Position: Q4 2017 in Review

Frontier Capital Management sold out of Celldex Therapeutics (CLDX) in Q4 2017, closing a stake of 11,609 shares — an estimated $498K sold.

Frontier Capital Management first reported a position in CLDX in Q2 2014 and held it in 14 quarters. The position peaked at $62.9M in Q2 2015. 135 funds tracked by Wall St. Rank hold CLDX as of Q4 2017.

  • Frontier Capital Management reported no remaining Celldex Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Frontier Capital Management sold 11,609 Celldex Therapeutics shares in Q4 2017, an estimated $498K.
  • Frontier Capital Management first reported a position in Celldex Therapeutics in Q2 2014 and held it in 14 quarters.
  • Frontier Capital Management's Celldex Therapeutics position peaked at $62.9M in Q2 2015.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2017.

Based on Frontier Capital Management's 13F filing for Q4 2017, filed 18 Jan 2018.